Printer Friendly
The Free Library
22,741,889 articles and books

AMGEN EARNINGS ZOOM 23 PERCENT.



Byline: Dave McNary Daily News Staff Writer

Biotechnology giant Amgen Inc., continuing to post impressive results, reported Thursday a 23 percent gain in fourth-quarter earnings to $178 million, or 64 cents a share.

The results, released after the stock market closed, were a penny or two better than Wall Street analysts had expected. Sales for Thousand Oaks-based Amgen, the world's largest biotech bi·o·tech  
n. Informal
Biotechnology.


biotech
Noun

short for biotechnology

Noun 1.
 concern, rose 16 percent to $593.5 million.

James McCamant, editor of the Medical Technology Stock Letter, said Amgen has achieved its position of prominence due to savvy marketing of its two flagship products A primary product of a company, which is typically why the company was founded and/or what made it well known. For example, MS-DOS, Windows and the Microsoft Office suite have been flagship products of Microsoft. CorelDRAW is a flagship product of Corel Corporation.  - red-cell stimulator Epogen and white-cell booster Neupogen.

``Amgen continues to execute beautifully on the marketing side,'' McCamant said. ``The results reflect strong skills in marketing and dealing with government agencies on reimbursements for customers.''

Epogen sales rose 22 percent to $289 million while Neupogen revenues gained 10 percent to $270 million.

McCamant said the key issue for Amgen remains development of additional strong products such as a drug for treating obesity or its MGDF MGDF Megakaryocyte Growth and Development Factor  drug, a copy of a protein that produces platelets, which make blood clot blood clot
n.
A semisolid, gelatinous mass of coagulated blood that consists of red blood cells, white blood cells, and platelets in a fibrin network.
. The fat-gene drug could be on the market by 2000 while MGDF could be sold by 1999, according to according to
prep.
1. As stated or indicated by; on the authority of: according to historians.

2. In keeping with: according to instructions.

3.
 analysts.

Earlier this month, Amgen stopped a late-stage trial of a potentially blockbuster drug A blockbuster drug is a drug generating more than $1 billion of revenue for its owner each year. The search for blockbusters has been the foundation of the R&D strategy adopted by big pharmaceutical companies, but this looks set to change.  to treat Lou Gehrig's disease Lou Geh·rig's disease
n.
See amyotrophic lateral sclerosis.
 when testing showed it was ineffective.

McCamant said Amgen is likely to receive approval for its stem-cell factor drug for patients receiving chemotherapy, but added that the market for it is relatively small compared with Epogen and Neupogen.

Amgen noted Thursday that it began human trials of six potential new products last year.

For all of 1996, Amgen's earnings rose 26 percent to $680 million, or $2.42 a share, from $538 million, or $1.92 a share, in 1995. Revenues rose 15 percent to $2.24 billion.
COPYRIGHT 1997 Daily News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1997, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:BUSINESS
Publication:Daily News (Los Angeles, CA)
Article Type:Statistical Data Included
Geographic Code:1USA
Date:Jan 24, 1997
Words:309
Previous Article:GROCERS TOP 4TH-QUARTER EXPECTATIONS.
Next Article:COMPANY PITCHING $60 LIFETIME NET USE.
Topics:



Related Articles
AMGEN TOPS EXPECTATIONS OF ANALYSTS.
AMGEN INC. SHARES DOWN DESPITE EARNINGS OUTLOOK.
RUMORS FLYING OVER AMGEN.
IN BRIEF.
RULING MAY AID AMGEN EARNINGS.
AMGEN INCOME BEATS FORECAST.
IN BRIEF.
ANOTHER BIG DAY; LEGAL WIN BOOSTS AMGEN STOCK.
AMGEN STOCK'S SLIDE PERSISTS.
AMGEN REPORTS REVENUES ROSE 18 PERCENT IN 1995.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters